Life sciences briefing: Tuesday, Sept. 11, 2007
Featured companies: Enobia, F-star, N Spine, Omni Life Science
Enobia splints together $38M for bone disorders — Montreal’s Enobia, a biotech focused on aiming drugs specifically at bone diseases, raised C$40.1 million ($38 million) in a second funding round. Investors included OrbiMed Advisors, CTI Life Sciences Fund, the Fonds de solidarite FTQ, Desjardins Venture Capital, Lothian Partners and T2C2/Bio 2000.
Enobia intends to deliver bone-related drugs directly to bone tissue in order to reduce both dosages and possible… Continue Reading
Aquapharm Biodiscovery nets $8.3M for marine-based antibiotics
Aquapharm Biodiscovery, a Scottish biotech aiming to discover new antibiotics and antioxidants from marine organisms, raised $8.3 million (£4 million) in a second funding round (PDF). The company, based near Oban in the European Center for Marine Biotechnology, harvests and cultures marine microbes in order to screen them for new biochemicals that might serve as drugs or food and cosmetics additives.
Aescap Venture led the round, joined by Tate & Lyle Ventures, Scottish Enterprise, NESTA Investments… Continue Reading